These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 12686329)

  • 1. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
    Montalescot G; Bal-dit-Sollier C; Chibedi D; Collet JP; Soulat T; Dalby M; Choussat R; Cohen A; Slama M; Steg PG; Dubois-Randé JL; Metzger JP; Tarragano F; Guermonprez JL; Drouet L;
    Am J Cardiol; 2003 Apr; 91(8):925-30. PubMed ID: 12686329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
    Montalescot G; Collet JP; Lison L; Choussat R; Ankri A; Vicaut E; Perlemuter K; Philippe F; Drobinski G; Thomas D
    J Am Coll Cardiol; 2000 Jul; 36(1):110-4. PubMed ID: 10898421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.
    Montalescot G; Philippe F; Ankri A; Vicaut E; Bearez E; Poulard JE; Carrie D; Flammang D; Dutoit A; Carayon A; Jardel C; Chevrot M; Bastard JP; Bigonzi F; Thomas D
    Circulation; 1998 Jul; 98(4):294-9. PubMed ID: 9711933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
    Berkowitz SD; Stinnett S; Cohen M; Fromell GJ; Bigonzi F;
    Am J Cardiol; 2001 Dec; 88(11):1230-4. PubMed ID: 11728348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of low-molecular-weight heparin in the management of acute coronary syndromes.
    Cohen M
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):55S-61S. PubMed ID: 12644342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of enoxaparin and dalteparin with unfractionated heparin in the treatment of non-ST elevated acute coronary syndrome.
    Ahmed M; Tariq M; Noor L; Din SU; Hafizullah M
    J Ayub Med Coll Abbottabad; 2011; 23(3):60-3. PubMed ID: 23272437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the use of unfractionated heparin in acute coronary syndrome outmoded?
    Chiquette E; Chilton R
    Curr Atheroscler Rep; 2004 Mar; 6(2):94-100. PubMed ID: 15023292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
    Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
    Kaul S; Shah PK
    J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction.
    Hödl R; Huber K; Kraxner W; Nikfardjam M; Schumacher M; Fruhwald FM; Zorn G; Wonisch M; Klein W
    Am J Cardiol; 2002 Mar; 89(5):589-92. PubMed ID: 11867046
    [No Abstract]   [Full Text] [Related]  

  • 13. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
    Antman EM
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
    Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
    Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
    Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
    Fox KA
    Am J Cardiol; 1999 Sep; 84(5A):26M-31M. PubMed ID: 10505540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups.
    Cohen M; Antman EM; Gurfinkel EP; Radley D;
    J Thromb Thrombolysis; 2001 Dec; 12(3):199-206. PubMed ID: 11981102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
    Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.